You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Antibody Drug Conjugates

Antibody-drug conjugates, or ADCs, are a new class of highly potent biopharmaceutical drug composed of an antibody linked to a biologically active drug compound.

ADC process flow and Applications

These novel, targeted agents combine the unique, high specificity, properties and anti-tumor activity of monoclonal antibodies (mAbs) that are tumor-specific but not sufficiently cytotoxic, with the potent cell killing activity of cytotoxic small molecule drugs that are too toxic to be used on their own.

Because the process involves the expansion and purification of mAb-based proteins, ADC bioprocessing begins with the same workflow for regular protein therapeutics. After this phase, further steps are taken for ADC development.



Conjugation ►


Drug is chemically linked to the purified antibody


Purification ►


Resin screening
Polish chromatography 
Scale-down validation
Tangential flow filtration




Filter screening
Tangential flow filtration

Repligen solutions​​​​​